PAVmed
PAVM
19 hedge funds and large institutions have $1.38M invested in PAVmed in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
48% more capital invested
Capital invested by funds: $932K → $1.38M (+$447K)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.03% less ownership
Funds ownership: 0.39% → 0.36% (-0.03%)
14% less funds holding
Funds holding: 22 → 19 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$102K |
| 2 |
OWP
Obermeyer Wealth Partners
Aspen,
Colorado
|
+$22K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.08K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$491 |
| 5 |
AF
Allworth Financial
Folsom,
California
|
+$31 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Axiom Advisory
San Diego,
California
|
-$70.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$20.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14.7K |
| 4 |
VF
Virtu Financial
New York
|
-$12K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.1K |
PAVM Hedge Fund Activity: Q3 2024 in Review
19 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q3 2024, worth a combined $1.38M — up 48% from $932K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PAVM and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was First Manhattan, adding an estimated $102K. The largest seller was Axiom Advisory, exiting entirely with an estimated $70.7K sold.
- 19 institutional investors held PAVmed (PAVM) as of Q3 2024, down from 22 in Q2 2024.
- Funds reported $1.38M of PAVmed stock for Q3 2024, up 48% quarter-over-quarter.
- 1 fund opened new PAVmed positions in Q3 2024 and 4 closed out, a net change of -3 holders.
- The largest PAVmed buyer in Q3 2024 was First Manhattan, an estimated $102K added.
- The largest PAVmed seller in Q3 2024 was Axiom Advisory, an estimated $70.7K sold.
Based on aggregated 13F filings for Q3 2024.